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We describe the case of a 14 year old girl, followed by
our Pediatric Allergology and Immunology Service for
persistent rhinitis and asthma. The child suffered from
asthma since the age of three years with a worsening of
symptoms during the winter months. At 4 years of life,
she was hospitalized for the first severe asthma episode.
The SPT were positive for dust mites, Alternaria, pollens
of grasses, Cypress, Birch, Plane, epithelium of dog and
cat, fish and soy. She started a fish and soy free diet and
therapy with ICS (50 mcg daily for 2), antihistamine and
antileukotriene. At six years of life she performed spiro-
metry, that showed moderate airflow obstruction (FEV1
75.8%) and significant dilatation after salbutamol (+16%).
For persistence of asthma despite the therapy, at the age
of 8 years she added LABA to the ICS (25/125 mcg daily
for 2), with significant improvement for the next two
years; spirometry normalized (FEV1 88.2%). When ten,
she started with almost daily wheezing that required the
use of OCS; spirometry showed severe bronchial obstruc-
tion and restriction (FEV1 58.8%). Chest X-ray was per-
formed, showing peribronchial infiltration and air
trapping; ph-metry, sweat test and Mantoux were nega-
tive; HRCT showed areas of thickening with appearance
“ground glass” air trapping and bronchiectasis predomi-
nantly in the upper lobes. Immunological and autoim-
mune evaluation were negative. Monitoring with the Peak
Flow Meter showed the persistence of frequent and severe
symptoms; FEV1 was 48.5% with expansion of 28.6% after
salbutamol. The girl was considered a candidate for ther-
apy with omalizumab and this was started in Autumn
2011 (575 mg/2 weeks) with significant improvement
(FEV1 100.5%). To date she is still treated with omalizu-
mab, plus therapy with CSI + LABA, antileukotriene and
antihistamine, with good control of asthma. On the basis
of our experience, the use of omalizumab is an effective
treatment for asthma resistant to common therapies, to
reduce bronchial reactivity, symptoms and use of OCS.
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